Clinical trial
Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.
NCT02334709 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.
- Lead sponsor
- University Hospital, Ghent
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 28, 2014
- Completion date
- August 31, 2016
- Enrollment
- 13 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.